Table 1 Summary of included trials
Author NCT identifier FDA identifier | Country | N | Arms | Mean age | Baseline MADRS score | % non-white | % female | Follow-up | Study quality |
|---|---|---|---|---|---|---|---|---|---|
Alvarez et al NCT00839423 11492Aa | Non-US | 429 | V 5 V 10 mg VLFX 225 mg | 43.3 | 34.0 | 8.0 | 62.7 | 6 weeks | Good |
Mahableshwarker et al NCT00672620 304b | US | 611 | V 2.5 mg V 5 mg DLX 60 mg placebo | 42.7 | 29.8 | 26.0 | 63.5 | 8 weeks | Fair |
Baldwin et al NCT00635219 11984Ab | Non-US | 776 | V 2.5 mg V 5 mg V 10 mg DLX 60 mg placebo | 44.9 | 31.9 | 21 | 68.1 | 8 weeks | Fair |
Jain et al NCT00672958 303b | US | 600 | V 5 mg placebo | 42.4 | 34.1 | 29.2 | 58.3 | 6 weeks | Fair |
Katona et al NCT00811252 12541Aa | US and Non-US | 453 | V 5 mg DLX 60 mg placebo | 70.6 | 30.5 | 5.3 | 65.7 | 8 weeks | Good |
Henigsberg et alNCT00735709 305a | Non-US | 560 | V 1 mg V 5 mg V 10 mg placebo | 46.4 | 30.8 | 13.8 | 62.7 | 8 weeks | Poor |
Boulenger et al NCT01140906 13267Aa | Non-US | 608 | V 15 mg V 20 mg DLX 60 mg placebo | 46.7 | 31.4 | 1.8 | 65.9 | 8 weeks | Fair |
McIntyre et al NCT01422213 FOCUS | US and Non-US | 598 | V 10 mg V 20 mg placebo | 45.7 | 31.5 | 5.5 | 66.2 | 8 weeks | Good |
Unpublished NCT01153009 315a | US | 614 | V 15 mg V 20 mg DLX 60 mg placebo | 42.9 | 32.1 | 23.4 | 73.8 | 8 weeks | Fairc |
Unpublished NCT01163266 316a | US | 462 | V 10 mg V 20 mg placebo | 42.8 | 32.2 | 30.1 | 72.5 | 8 weeks | Fairc |
Unpublished NCT01179516 317b | US | 434 | V 10 mg V 15 mg placebo | 45.1 | 33.7 | 25.8 | 70.1 | 8 weeks | Fairc |